Abiomed's heart pump gets EU nod
(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.
The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.
The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.
Impella cVAD is still not approved in the United States.
Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
India stepped up its efforts on Tuesday to prevent an outbreak of the deadly Ebola virus, conducting mock drills at its airports and installing surveillance systems. Full Article